Working... Menu
Trial record 1 of 1 for:    NCT03117816 | Recruiting, Not yet recruiting Studies
Previous Study | Return to List | Next Study

ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission (ENDURE-CML-IX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03117816
Recruitment Status : Recruiting
First Posted : April 18, 2017
Last Update Posted : May 21, 2019
Deutsche Krebshilfe e.V., Bonn (Germany)
AOP Orphan Pharmaceuticals AG
Information provided by (Responsible Party):
Kerstin Balthasar, Philipps University Marburg Medical Center

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 2021
  Estimated Study Completion Date : December 2024
Mahon, F., Richter, J., Guilhot, J., Muller, M. C., Dietz, C., Porkka, K., Hjorth-Hansen, H., Gruber, F., Panagoitidis, P., Ossenkoppele, G. J., Mayer, J., Almeida, A., Machova Polakova, K., Ehrencrona, H., Kairisto, V., Berger, M. G., Olsson stromberg, U., Mustjoki, S., Hochhaus, A., Pfirrmann, M., & Saussele, S. (2014). Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study. Blood, 124(21), 151. Accessed March 07, 2017. Retrieved from